Sysmex Raises Full-Year Forecast on Strong Americas Sales

Sysmex posted a 17.3% year-over-year increase in first-half sales, reaching ¥272.822 billion, fueled by strong performance in the Americas. The company also revised its full-year forecast upwards, anticipating increased profitability due to continued momentum in the Americas and ongoing cost optimization efforts. This positive revision comes despite a ¥5.769 billion impairment loss recognized on its acquisition of Sysmex BioMajesty, indicating the company is able to offset the impact of the write-down with improved core business performance.

The Americas region saw a significant 26.1% jump in sales to ¥77.109 billion, driven by robust demand for hematology instruments, reagents, and maintenance services. The EMEA region also contributed positively, with sales rising 19.0% to ¥83.960 billion. While sales in China declined 10.4%, the company’s overall growth was buoyed by the strong performance in other key markets. This geographical diversification appears to be paying dividends, cushioning the impact of regional headwinds.

Despite the increase in sales, net profit for the first half decreased 5.7% to ¥17.933 billion, largely attributable to the impairment loss on the Sysmex BioMajesty acquisition and increased research and development expenses. However, the upward revision of the full-year forecast suggests the company anticipates a stronger second half, potentially driven by further cost efficiencies and sustained growth in the Americas. The company also reported a significant increase in cash and cash equivalents, rising to ¥120.636 billion, providing financial flexibility.

Sysmex’s revised forecast signals a degree of confidence in its growth trajectory, despite the challenges posed by the impairment loss. The company's ability to leverage strong performance in key regions, particularly the Americas, to offset these challenges underscores its operational resilience. The improved outlook places Sysmex on a path to exceed prior expectations, capitalizing on favorable currency exchange rates and a strategic focus on cost control.